Form 4: Vir Biotechnology Director Sells Shares to Cover Tax Obligations

Director George A. Scangos sold shares of Vir Biotechnology to cover tax withholding obligations related to vesting restricted stock units.

Summary

• On February 18, 2025, George A. Scangos, a director of Vir Biotechnology, Inc., sold 10,964 shares of common stock at a price of $9.8117 per share.
• The sale was executed to cover the issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units.
• Following the transaction, Scangos directly owns 708,295 shares of common stock.
• Scangos also indirectly owns shares through various trusts, including the George A Scangos 2023 Annuity Trust (1,151,730 shares), shares held by his spouse (598,270 shares), the Leslie Wilson 2023 Annuity Trust (1,151,730 shares), the Scangos-Wilson Family Trust (33,629 shares), and the Scangos 2018 Grandchildren's Trust (179,930 shares).

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine sale to cover tax obligations and doesn't necessarily indicate a positive or negative outlook on the company's performance.

Industry Context

Sales of shares by company insiders are a common occurrence, often related to personal financial planning or tax obligations. The market typically views these transactions in the context of the overall insider holdings and the reasons behind the sale.

Stakeholder Impact

• The sale of shares by a director could have a minor impact on shareholder sentiment, but is unlikely to be significant given the reason for the sale.

Key Dates

Keywords

Form 4, Vir Biotechnology, Director, Scangos, Share Sale, Tax Obligations, Restricted Stock Units, Beneficial Ownership